Introduction: Members of the Human Epidermal Receptor [HER] family of receptor tyrosine kinases, such as HER2 and EGFR proteins are overexpressed in several epithelial malignancies and serve as effective therapeutic targets in cancer management. However, their role in prostate cancer development has been sparingly explored and with contrasting findings. Notably their relationship with prostate cancers cases seen in Sub-Saharan Africa is yet to be explored. Design: A retrospective study involving histologically diagnosed cases of adenocarcinomas of the prostate. Cases were classed according to the WHO/ISUP Gleason Prognostic groups [G1 - G5]. Immunohistochemical analysis was performed using monoclonal antibodies for HER2 and EGFR, while in situ hybridization employed DNA probes for the corresponding genes. Scores of +2 and +3 were regarded as positive for both antibodies, while a target gene: centromere ratio of >2 was set as the threshold for amplification. Results: A total of 44 cases were included in the study. The acinar type was the commonest morphologically, with Gleason group 5 [Gleason scores 8 - 10] accounting for close to half of the cases [47.7%]. The HER2 antibody stained negatively in the majority of cases [93.2%], being positive in only 3 [6.8%] of cases seen. High level expression of EGFR [+2/+3] was observed in 25% of cases, low level expression was identified in 6 [13.6%] cases. All HER2 positive malignancies displayed overexpression of EGFR. In situ-hybridization revealed the absence of high level amplification for both HER2 and EGFR, while polysomy was not detected in any of the cases. Conclusion: The overexpression of EGFR in prostate cancers has been demonstrated in a native African population, affirming its suitability for targeted therapy. Overexpression of HER2 in prostate cancer is inconstant, and amplification of the HER2 gene is less frequent than as compared to malignancies of the Breast and Ovary. There’s a need for a standardized protocol for assessing HER2 in prostate cancer.
References
[1]
Wieduwilt, M.J. and Moasser, M.M. (2008) The Epidermal Growth Factor Receptor Family: Biology Driving Targeted Therapeutics. Cellular and Molecular Life Sciences, 65, 1566-1584. https://doi.org/10.1007/s00018-008-7440-8
[2]
Arteaga, C.L. and Engelman, J.A. (2014) ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell, 25, 282-303. https://doi.org/10.1016/j.ccr.2014.02.025
[3]
Dhomen, N.S., Mariadason, J., Tebbutt, N. and Scott, A.M. (2012) Therapeutic Targeting of the Epidermal Growth Factor Receptor in Human Cancer. Critical Reviews in Oncogenesis, 17, 31-50. https://doi.org/10.1615/CritRevOncog.v17.i1.40
[4]
Nelson, E.L. (2014) HER2/Neu: An Increasingly Important Therapeutic Target: Part 2 Distribution of HER2/Neu Overexpression and Gene Amplification by Organ, Tumour Site and Histology. Journal of Clinical Investigation (London), 4, 705-728.
https://doi.org/10.4155/cli.14.62
[5]
Wen, Y., Hu, M.C.T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D.H., et al. (2000) HER-2/Neu Promotes Androgen Independent Survival and Growth of Prostate Cancer Cells via the Akt Pathway. Cancer Research, 60, 6841-6845.
[6]
Guérin, O., Fischel, J.L., Ferrero, J.-M., Bozec, A. and Milano, G. (2010) EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals, 3, 2238-2247. https://doi.org/10.3390/ph3072238
[7]
Sanchez, K.M., Sweeney, C.J., Mass, R., Koch, M.O., Eckert, G.J., Geary, W.A., et al. (2002) Evaluation of HER-2/Neu Expression in Prostatic Adenocarcinoma: A Request for a Standardized Organ Specific Methodology. Cancer, 95, 1650-1655.
https://doi.org/10.1002/cncr.10839
[8]
Ayala, G., Frolov, A., Chatterjee, D., He, D., Hilsenbeck, S. and Ittmann, M. (2015) Expression of ERG Protein in Prostate Cancer: Variability and Biological Correlates. Endocrine-Related Cancer, 22, 277-287. https://doi.org/10.1530/ERC-14-0586
[9]
Adeloye, D., David, R.A., Aderemi, A.V., Iseolorunkanmi, A., Oyedokun, A., Iweala, E.E.J., et al. (2016) An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. PLoS ONE, 11, e0153496.
https://doi.org/10.1371/journal.pone.0153496
[10]
Ullen, A., Lennartsson, L., Harmenberg, U., Lennernas, B., Majumuder, K., Holmberg, A.R., et al. (2005) Prostate Cancer Cell Lines Lack Amplification: Overexpression of HER2. Acta Oncologica, 44, 490-495.
https://doi.org/10.1080/02841860510029888
[11]
Lyne, J.C., Naraghi, R.M., Melhem, M.A., et al. (1995) Human Prostate Cancer Cells Respond to But Do Not Express Neu Differentiation Factor (NDF) in Spite of HER2/Neu Gene Amplification and Protein Overexpression. The Cancer Journal from Scientific American, 3, 21-30.
[12]
Sadasivan, R., Morgan, R., Jennings, S., Austenfeld, M., Van Veldhuizen, P., Stephens, R., et al. (1993) Overexpression of Her-2/Neu May Be an Indicator of Poor Prognosis in Prostate Cancer. Journal of Urology, 150, 126-131.
https://doi.org/10.1016/S0022-5347(17)35413-7
[13]
Botswick, D.G. (1994) c-erbB-2 Oncogene Expression in Prostate Intraepithelial Neoplasia. Journal of the National Cancer Institute, 86, 1108-1110.
https://doi.org/10.1093/jnci/86.15.1108
[14]
Niyat, M.M. (2015) Prognostic Value of Her2/Neu Expression in Patients with Prostate Cancer: A Systematic Review. Reviews in Clinical Medicine, 2, 168-173.
[15]
Chen, Y., Lin, Y., Nie, P., Jiang, W., Liu, Y., Yuan, R., et al. (2017) Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma. Medical Science Monitor, 23, 1768-1774. https://doi.org/10.12659/MSM.900977
[16]
American Cancer Society (2019) Key Statistics for Prostate Cancer.
http://www.cancer.org
[17]
Daoud, S.A., Darweesh, M.F. and Sharaf, R.M. (2016) HER2/Neu Immunohistochemical Overexpression in Prostatic Adenocarcinoma in Relation to Tumor Pathological Behavior. Middle East Journal of Scientific Research, 24, 459-464.
[18]
Cancer Research UK. Prostate Cancer Statistics.
http://www.cancerresearchuk.org
[19]
Tkachenko, P.V. (2017) Clinical-Morphological Prognostic Characteristics of Prostate Cancer. German Science Herald, 2, 14-18.
[20]
Dube, V.E., Farrow, G.M. and Greene, L.F. (1973) Prostatic Adenocarcinoma of Ductal Origin. Cancer, 32, 402-409.
https://doi.org/10.1002/1097-0142(197308)32:2<402::AID-CNCR2820320218>3.0.CO;2-Q
[21]
Odubanjo, M.O., Banjo, A.A.F., Ayoola, S., Abdulkareem, F.B., Anunobi, C.C. and Olayinka, A.A. (2013) The Clincopathologic Pattern of Prostate Carcinoma in Lagos, Nigeria. North American Journal of Medical Sciences, 6, 71-75.
[22]
Mofid, B., Jalali Nadoushan, M.R., Rakhsha, A., Mirzaei, H.R. and Zeinali, L. (2010) Epidermal Growth Factor Receptor Gene in Prostate Cancer after Radical Prostatectomy. Iranian Journal of Cancer Prevention, 3, 174-177.
[23]
Schlomm, T., Kirtsein, P., Iwers, L., Daniel, B., Steuber, T., Walz, J., et al. (2007) Clinical Significance of Epidermal Growth factor Receptor Overexpression and Gene Copy Number Gains in Prostate Cancer. Clinical Cancer Research, 13, 6579-6584.
https://doi.org/10.1158/1078-0432.CCR-07-1257
[24]
Peraldo-Neia, C., Migliardi, G., Mello-Grand, M., Montumerro, F., Segir, R., Pignochino, Y., et al. (2011) Epidermal Growth Factor Receptor (EGFR) Mutation Analysis, Gene Expression Profiling and EGFR Protein Expression in Primary Prostate Cancer. BMC Cancer, 11, 31. https://doi.org/10.1186/1471-2407-11-31
[25]
Olapade-Olaopa, E.O., Moscatello, D.K., MacKay, E.H., Horsburgh, T., Sandhu, D.P.S., Terry, T.R., et al. (2000) Evidence for the Differential Expression of a Variant EGF Receptor Protein in Human Prostate Cancer. British Journal of Cancer, 82, 186-194. https://doi.org/10.1054/bjoc.1999.0898
[26]
Ratan, H.L., Gescher, A., Steward, W.P. and Mellon, J.K. (2003) ErbB Receptors: Possible Therapeutic Targets in Prostate Cancer? BJU International, 92, 890-895.
https://doi.org/10.1111/j.1464-410X.2003.04503.x
[27]
Minner, S., Jessen, B., Stiedenroth, L., Burandt, E., Kollerman, J., Mirlacher, M., et al. (2010) Low Level HER2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer. Clinical Cancer Research, 16, 1553-1560. https://doi.org/10.1158/1078-0432.CCR-09-2546
[28]
Visakorpi, T., Kallioniemi, O.P., Koivula, T., Harvey, J. and Isola, J. (1992) Expression of Epidermal Growth Factor Receptor and ERBB2 (HER-2/Neu) Oncoprotein in Prostatic Carcinomas. Modern Pathology, 5, 643-648.
[29]
Kaltz-Wittmer, C., Klenk, U., Glaessgen, A., et al. (2000) FISH Analysis of Gene Aberrations (MYC, CCND1, ERBB2, RB, and AR) in Advanced Prostatic Carcinoma before and after Androgen Deprivation Therapy. Laboratory Investigation, 80, 1455-1464. https://doi.org/10.1038/labinvest.3780152
[30]
Ross, J.S., Nazeer, T., Church, K., Amato, C., Figge, H., Rifkin, M.D. and Fisher, H.A. (1993) Contribution of HER-2/Neu Oncogene Expression to Tumor Grade and DNA Content Analysis in the Prediction of Prostatic Carcinoma Metastasis. Cancer, 72, 3020-3028.
https://doi.org/10.1002/1097-0142(19931115)72:10<3020::AID-CNCR2820721026>3.0. CO;2-#
[31]
Da Cruz, J.A.S., dos Reis, S.T., Guariero, M.E.S., Leite, K.R., Srougi, M. and Passerotti, C.C. (2017) Association between HER-2/Neu(erbB-2) Overexpression and Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy. Annals of Urology Research, 1, 1006.
[32]
Oxley, J.D., Winkler, M.H., Gillatt, D.A. and Peat, D.S. (2002) Her2/Neu Oncogene Amplification in Clinically Localized Prostate Cancer. Journal of Clinical Pathology, 55, 118-120. https://doi.org/10.1136/jcp.55.2.118
[33]
Bass, B.P., Engel, K.B., Greytak, S.R. and Moore, H.M. (2014) A Review of Preanalytical Factors Affecting Molecular, Protein, and Morphological Analysis of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue: How Well Do You Know Your FFPE Specimen? Archives of Pathology & Laboratory Medicine, 138, 1520-1530.
https://doi.org/10.5858/arpa.2013-0691-RA
